# TCR-T Therapy Sector

Canonical URL: https://biopharmsignal.com/sector/tcr-t-therapy

TCR-T Therapy includes companies engineering T-cell receptors to recognize specific antigens presented by tumor or diseased cells. It is a specialized cell-therapy category with particular relevance in solid tumors and antigen-defined precision immuno-oncology.

Companies currently grouped under TCR-T Therapy: 1

## Recent Sector News

- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-u-s-fda-breakthrough-therapy-designation-granted-to-letetresgene-autoleucel-lete-cel-for-treatment-of-myxoid-round-cell-liposarcoma-mrcls) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025](https://biopharmsignal.com/news/ADAP/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025](https://biopharmsignal.com/news/ADAP/adaptimmune-to-report-full-year-and-q4-2024-financial-and-business-updates-on-thursday-march-20-2025) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Provides Q4 and Full Year 2024 Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-provides-q4-and-full-year-2024-business-update) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025](https://biopharmsignal.com/news/ADAP/adaptimmune-to-report-q1-2025-financial-and-business-updates-on-tuesday-may-13-2025) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Reports Q1 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q1-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-tecelra-lete-cel-afami-cel-and-uza-cel-cell-therapies-to-us-worldmeds) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Reports Q2 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADAP/adaptimmune-reports-q2-financial-results-and-provides-business-update) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Announces Delisting from Nasdaq](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-delisting-from-nasdaq) — Source: Adaptimmune Therapeutics plc
- 2026-06-25 13:46 EST — ADAP — [Adaptimmune Announces Changes to Board and Executive Leadership Team](https://biopharmsignal.com/news/ADAP/adaptimmune-announces-changes-to-board-and-executive-leadership-team) — Source: Adaptimmune Therapeutics plc

## Companies

- [ADAP](https://biopharmsignal.com/company/ADAP) — Adaptimmune Therapeutics plc